Table 3.
Distribution of tumor phenotypes among screening-detected cancers (n = 1,297) and categories of interval cancers (n = 948)
| |
Screening-detected cancers |
True interval cancers |
False negatives |
Minimal-sign cancers |
Occult tumors |
|
|---|---|---|---|---|---|---|
| n = 1,297 | n = 455 | n = 224 | n = 166 | n = 103 (%) | P value † | |
|
Tumor phenotype |
|
|
|
|
|
|
| Luminal A |
629 (68.3) |
197 (50.9)* |
124 (68.1) |
79 (59.4) |
62 (79.5) |
|
| Luminal B |
139 (15.1) |
60 (15.5) |
29 (15.9) |
18 (13.5) |
8 (10.3) |
|
| HER2 |
62 (6.7) |
53 (13.7)* |
14 (7.7) |
13 (9.8) |
3 (3.8) |
|
| Triple-negative |
91 (9.9)* |
77 (19.9)* |
15 (8.2) |
23 (17.3) |
5 (6.4) |
<0.001 |
| Unknown | 376 | 68 | 42 | 33 | 25 |
Results are expressed as number (%). Tumor phenotype = Luminal A (ER+/HER2- or PR+/HER2-); Luminal B (ER+/HER2+ or PR+/HER2+); HER2 (ER-/PR-/HER2+); Triple-negative (ER-/PR-/HER2-). *Standardized Pearson residuals with statistically significant deviation between observed and expected values. †The distribution of tumor phenotype was compared among the study groups using the two-sided Chi-square test. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.